P2RY12 and atrial fibrillation: [12, 22–24] The PIONEER AF-PCI study, the first one of them, compared three treatment strategies in AF patients after PCI and the study demonstrated the superiority in safety outcomes with DAT (rivaroxaban 15 mg once daily plus a P2Y12 inhibitor, mostly clopidogrel) relative to traditional TAT with DAPT plus VKA.